Skip to content

DE-PHARMA

Active Public limited companyfounded 2004active for 21 yearsRue Charles Piron (G.) 66, 7011 MonsKBO/BCE: BE 0870.252.722

Lifetime

20 annual accounts with figures on one time axis, 21 filings since 2005
peak of €244,243 in 2010
€76,071▼ 27.8%
lowest -€84,749 in 2008
€9,000▼ 73.7%
peak of €1.2m in 2025
€1.2m▲ 0.7%
€382,518▼ 1.7%
peak of 2.2 FTE in 2008
-not published
Board1 name since 2010
1 director
Documentsfilings and deeds
21-05-202671 days before the deadline
2025micro format
Gross margin from €105,375 to €76,071Result from €34,274 to €9,000Investments €210,972

Key points

from the 2025 annual accounts

Equity

€1.2m ▲ 0.7%

DE-PHARMA has made a profit without a break since 2014.

Investments

€210,972 3.3 times depreciation
202220232025

Green is investment, beige is depreciation. Machinery stands 378.2% higher than in 2024.

Filings

21 annual accounts since 2005
AprilJune31 JulyOctober20052010201520202025

The last five annual accounts were filed 46 to 71 days before the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 14,774 companies had the same profile as DE-PHARMA has now. Each dot stands for 37 companies, two years later.

96.1%
were still trading
3.5%
stopped another way
0.2%
went bankrupt
  • Small
  • 20 years or older
  • solvency 30% or more
  • a profit under 5% of the balance sheet

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 14,774 companies, not a prediction for DE-PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 10-05-2023
  • 305 sharesdeed of 13-01-2014
  • 1 sharedeed of 13-01-2014
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0870252722
reappointed as director General meeting of 10-05-2023 · Gazette deed
Capital decrease of €215,728 to €62,272 The capital fell from €278,000 to €62,272 · General meeting of 26-12-2017 · Gazette deed
Registered office moved within Ghlin The registered office moved from Rue de Mons, 146 à 7011 Ghlin to Rue Charles Piron, 66 à 7011 Ghlin · (director) and (director) reappointed · appointed as managing director · General meeting of 10-05-2017 · Gazette deed
All 39 events

Comparable companies

same main activity, similar in size and age
Company
DE-PHARMA Mons €1.6m €76,071 76.1% -
AERTS-JANSSENS Schoten €1.6m €76,614 87.2% -
Apotheek Muide Ghent €1.4m €88,816 20.8% 0
ANTARES INVEST Celles (lez-Tournai) €1.8m €103,243 14.5% -
MONIN-DONNEZ Momignies €1.6m €81,707 28.3% -
DUVIPHAR Colfontaine €1.8m €100,405 0.9% -
GANS INVESTORS Scherpenheuvel-Zichem €2.0m €102,587 46.5% -

These companies have the same main activity as DE-PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €1.4m and €2m, founded between 1995 and 2010.

Official details

Source: KBO
Status
Active since 29-11-2004Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Joint committee
313Pharmacies and pricing offices · annual accounts 2025
Establishment unit
2.144.062.7591160 Auderghem, since 01-01-2005
Financial year end
31 December
Peppol
Reachable since 24-11-2025
Company details

Annual accounts 2025

≈ €370,000estimated
€1.6m▲ 0.1%
Filing
Filed on 21-05-2026, 71 days before the end of the filing period
Financials

Insights on DE-PHARMA

DE-PHARMA files the micro format. That format states no turnover. The gross margin rose from €73,800 in 2006 to €76,071 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about DE-PHARMA

What is the company number of DE-PHARMA?
The company number of DE-PHARMA is 0870.252.722. The VAT number is the same number with BE in front: BE 0870.252.722.
Where is DE-PHARMA based?
The registered office is at Rue Charles Piron (G.) 66, 7011 Mons.Company details
What does DE-PHARMA do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of DE-PHARMA?
DE-PHARMA is a public limited company (NV).
When was DE-PHARMA founded?
DE-PHARMA was founded on 29-11-2004.
Is DE-PHARMA still active?
Yes, DE-PHARMA is an active enterprise in the KBO register.
Which joint committee does DE-PHARMA fall under?
In its 2025 annual accounts, DE-PHARMA states joint committee 313 (Pharmacies and pricing offices).
What is the turnover of DE-PHARMA?
The turnover in financial year 2025 is about €370,000. This figure is estimated from the gross margin of €76,071 and 55 comparable companies (NACE 477). It probably lies between €190,000 and €550,000.Financials
Is DE-PHARMA profitable?
In financial year 2025, DE-PHARMA made a profit of €9,000.
Where can I find the annual accounts of DE-PHARMA?
DE-PHARMA filed 21 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of DE-PHARMA due?
DE-PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.